AbbVie Other Long-Term Assets 2010-2024 | ABBV

AbbVie other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • AbbVie other long-term assets for the quarter ending September 30, 2024 were $9.197B, a 48.39% increase year-over-year.
  • AbbVie other long-term assets for 2023 were $8.513B, a 52.81% increase from 2022.
  • AbbVie other long-term assets for 2022 were $5.571B, a 14.07% increase from 2021.
  • AbbVie other long-term assets for 2021 were $4.884B, a 0.68% increase from 2020.
AbbVie Annual Other Long-Term Assets
(Millions of US $)
2023 $8,513
2022 $5,571
2021 $4,884
2020 $4,851
2019 $2,288
2018 $1,208
2017 $1,326
2016 $1,212
2015 $1,149
2014 $1,480
2013 $767
2012 $835
2011 $784
2010 $
2009 $
AbbVie Quarterly Other Long-Term Assets
(Millions of US $)
2024-06-30 $9,197
2024-03-31 $9,067
2023-12-31 $8,513
2023-09-30 $7,094
2023-06-30 $6,198
2023-03-31 $5,800
2022-12-31 $5,571
2022-09-30 $5,382
2022-06-30 $5,033
2022-03-31 $5,083
2021-12-31 $4,884
2021-09-30 $4,747
2021-06-30 $4,808
2021-03-31 $4,792
2020-12-31 $4,851
2020-09-30 $3,936
2020-06-30 $4,009
2020-03-31 $2,638
2019-12-31 $2,288
2019-09-30 $1,677
2019-06-30 $1,589
2019-03-31 $1,567
2018-12-31 $1,208
2018-09-30 $943
2018-06-30 $909
2018-03-31 $903
2017-12-31 $1,326
2017-09-30 $1,327
2017-06-30 $1,305
2017-03-31 $1,263
2016-12-31 $1,212
2016-09-30 $1,550
2016-06-30 $1,445
2016-03-31 $1,328
2015-12-31 $1,149
2015-09-30 $1,235
2015-06-30 $1,181
2015-03-31 $1,755
2014-12-31 $1,480
2014-09-30 $801
2014-06-30 $795
2014-03-31 $803
2013-12-31 $767
2013-09-30 $1,150
2013-06-30 $1,693
2013-03-31 $1,715
2012-12-31 $835
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $784
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $352.544B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51